Autoimmune Encephalitis
Conditions
Brief summary
This study aims to establish an autoimmune encephalitis cohort and observe the prognosis of patients with different subtypes and subgroups (e.g. epilepsy subgroup and teratoma subgroup ). Clinical characteristics, biological samples, and imaging data will be collected to discover blood and imaging biomarkers for providing support for the treatment, early warning, and outcome prediction.
Interventions
OTHERbaseline data collection and follow-up
At the time of enrollment, baseline characteristics will be collected, and each subject will be followed up for 2 years through face-to-face, telephone, or online visits. During the follow-up period, the clinical prognosis will be recorded.
Sponsors
Xuanwu Hospital, Beijing
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* 1\. Gender and age are not limited; 2. Newly diagnosed autoimmune encephalitis according to at least one of the following three criteria: 1. According to the criteria of Graus et al in 2016, diagnosed as definite autoimmune limbic encephalitis 2. According to the criteria of Graus et al in 2016, diagnosed as possible autoimmune encephalitis and typical autoantibodies are detected in serum or cerebrospinal fluid 3. According to the criteria of Graus et al in 2021, diagnosed as possible or definite paraneoplastic neurological syndrome (excluding peripheral nervous system syndrome) 3. The patient or legal representative voluntarily signed the paper informed consent form. Additional inclusion criteria for patients in the epilepsy subgroup: patients diagnosed with epilepsy secondary to autoimmune encephalitis.
Exclusion criteria
* No additional
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in modified Rankin score (mRS) from baseline | 3months, 6 months, 12months, 24months | Change in modified Rankin score (mRS) from baseline at month 1, month 3, month 6(mRS : Minimum Score 0, Maximum score 6, higher scores mean a worse outcome). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Subjects With Occurrence | 12 months, 24 months | — |
| Change of Clinical Assessment Scale in Autoimmune Encephalitis (CASE) Score from Baseline | 3months, 6 months, 12months, 24months | The Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score is designed specifically to assess the severity of autoimmune disease. It is a general scoring system ranging from 0 to 27 and can be used as an alternative tool to assess the severity of patients with AE more accurately. Higher scores mean a worse clinical status. |
| Changes of pathogenic antibody titers from baseline | 3months, 6 months, 12months, 24months | — |
Countries
China
Contacts
Primary ContactJunwei Hao, MD; PhD
Outcome results
None listed